透視港股通丨港交所、騰訊獲加倉
北水總結
6月21日港股市場,北水成交淨買入12.32億,其中港股通(滬)成交淨賣出0.92億港元,港股通(深)成交淨買入13.24億港元。
北水淨買入最多的個股是港交所(00388)、騰訊(00700)、藥明生物(02269)。北水淨賣出最多的個股是中國移動(00941)、建設銀行(00939)、信達生物(01801)。

數據來源:盈立智投APP
十大成交活躍股

港股通(滬)十大活躍成交股

港股通(深)十大活躍成交股
數據來源:港交所
個股點評
港交所(00388)獲淨買入2.73億港元。消息面上,香港交易所首席執行官歐冠升近日接受採訪時表示,港交所考慮在北美和歐洲開設辦事處,他確認了在紐約設立辦事處的計劃,但表示還沒有最終決定其首個歐洲辦事處的地點。他還表示對下半年新股IPO活動感到樂觀。此外,港交所近期的員工流失情況已經紓緩,特別是過去兩三個月,流失率持續下降。
騰訊(00700)獲淨買入1.97億港元。消息面上,據財聯社報道,三位知情人士稱,騰訊控股週一向其員工宣佈正式成立“擴展現實“(XR)部門,正式將賭注押在虛擬世界的元宇宙概念上。消息人士稱,該部門的任務是爲騰訊建立包括軟件和硬件在內的擴展現實業務,並將成爲該公司互動娛樂事業羣(IEG)的一部分。
藥明生物(02269)獲淨買入1.58億港元。消息面上,藥明生物近日表示,截至4月,積壓訂單總額從2021年的136億美元增長至173億美元;公司的目標是最早在2022年8月/9月從未經證實名單中移除一個實體;到2025年,該公司預計將運營26-31款商業化產品,較3月份指引增加5個項目。
佳源國際控股(02768)再獲淨買入2837萬港元。消息面上,佳源國際控股發佈公告,公司向集團的選定僱員根據購股權計劃提呈授出1.305億份購股權,據悉,購股權行使價爲每股0.38港元。此外,佳源國際控股近日公佈,終止出售佳源服務73.56%股權。
阿裏健康(00241)獲淨買入2216萬港元。消息面上,阿裏健康此前與慧醫天下互聯網醫療平臺達成戰略合作。中金認爲,阿裏健康通過進一步加碼慢病險業務,針對慢病用戶的需求將健康管理前置,能夠滿足輕症、併發症、重疾各階段病程的不同需求,同時有望進一步提高公司自身嚴肅醫療屬性業務的客戶粘性,實現長期業務穩定性和盈利改善。
信達生物(01801)今日收漲逾13%,部分北水資金逢高拋售,全天淨賣出額5554萬港元。消息面上,信達生物公告,國家藥品監督管理局已經正式批準創新藥物PD-1抑制劑達伯舒(信迪利單抗注射液)聯合紫杉醇和順鉑或氟尿嘧啶和順鉑用於不可切除的局部晚期、復發或轉移性食管鱗癌的一線治療的新適應症上市申請。
建設銀行(00939)遭淨賣出7475萬港元。消息面上,東方金誠首席宏觀分析師王青判斷,當前經濟處於修復初期,政策面正着力引導銀行加大信貸投放力度,讓利實體經濟。着眼於激發企業和居民信貸需求,實際貸款利率仍存在下行可能性。
此外,寶新金融(01282)、中海油(00883)、快手-W(01024)分別獲淨買入9519萬、3892萬、385萬港元。而中國移動(00941)、天立教育(01773)分別遭淨賣出1億、809萬港元。
港股通最新持股比例排行

(港股通持股比例排行,交易所數據T+2日結算)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.